pharmaphorum11d
4th ALS Drug Development Summit
The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...
Pharmabiz19d
QurAlis announces positive data from phase 1 trial of QRL-101 evaluating biomarkers of ALS and epilepsy in healthy volunteers
QurAlis Corporation (QurAlis), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Fox 44 Waco News20d
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ...
The Globe and Mail22d
Knight Therapeutics to buy Paladin Pharma in bid to build out Canadian business
Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...